TORONTO – (COMMERCIAL THREAD) – The eighth paragraph of the press release dated June 1, 2021, should read … said Andrew Eibl, COO of Flosonics Medical (instead of … said Andrew Eibl, CEO of Flosonics Medical).
The updated version reads as follows:
OBIO SHARES THE RESULTS OF THE PILOT LAUNCH OF NEW TECHNOLOGIES THAT HELP MANAGE COVID-19
Innovative Canadian medical technology projects made possible by the Early Adopter Health Network
As the race to eradicate Covid-19 continues, the Ontario Bioscience Innovation Organization (OBIO®), a non-profit organization dedicated to advancing innovation and commercialization of health technologies in Ontario, shares the results of the pilot launch of its Early Adopter Health program. Network (EAHN) introduced last year. Four projects with new technologies have been adapted to meet the challenges of Covid-19, ranging from healthcare operations and disease / patient management to improving diagnosis or treatment.
“EAHN’s goal is to become the first to adopt local medical technology and help streamline the procurement process to help hospitals and healthcare providers provide better patient care,” said Gail Garland, President and CEO of OBIO. “The companies in our program were able to pivot their technologies in real time to help address some of the challenges presented by the COVID-19 pandemic and match them more effectively with clinical end users. ”
The four projects activated by EAHN include:
KA Imaging’s Reveal 35C is the world’s first x-ray detector that provides three different images (a standard digital x-ray, as well as bone and soft tissue images) and can be used at the bedside to better visualize the lungs. , especially in COVID-19 patients. Enhanced diagnostic imaging can be a game-changer in the ICU to assess whether patients with pneumonia need a ventilator, or how the disease is progressing, and can be easily deployed in a community hospital or clinic.
“With the support of EAHN, we were able to test Reveal in a clinical environment, allowing the radiologist to diagnose pneumonia with more confidence,” said Amol Karnick, President and CEO of KA Imaging. “The same facility has already received two additional systems to increase imaging capacity, proving that early adopters are critical to how quickly new technologies are implemented. ”
Patients with COVID-19 may have neurological and cardiopulmonary problems requiring repeated MRIs and CT scans. Given the virus’s half-life of 72 hours on plastic or metal, the surfaces of these machines can be contaminated, exposing healthcare workers and other patients to infection. Synaptive, along with its partners, has designed a single-use drape that can be safely discarded after each scan, an innovation that can prevent potential COVID-19 contamination and protect against other airborne viruses.
“The OBIO program provides us with the opportunity to design, test and validate our MRI drape solution in a real clinical scenario, with the collaboration of our UHN partners,” said Cameron Piron, president of Synaptive Medical. “The ability to work with major Ontario healthcare organizations through EAHN provides companies like Synaptive Medical with a Canadian customer base and experiences that reinforce our global value proposition.
FloPatch, the world’s first portable and wireless Doppler blood flow device, helps medical staff assess and monitor blood flow in critically ill patients by sending data remotely to mobile devices using low-power Bluetooth. energy, which is essential in the context of a pandemic. The low-cost ultrasonic sensor adheres to the patient’s neck, providing hands-free blood flow assessments and important clinical information for patients in the emergency department, operating room, general practice ward, and nursing units. intensive care.
“Through the Early Adopter Health Network, with support from the Northern Health Science Research Institute, we have been able to test FloPatch and advance the technology to market by facilitating engagement with hospitals here in Ontario. said Andrew Eibl, COO of Flosonics Medical.
Ironstone product development
Ironstone’s Revoxa ™ system increases the efficiency of oxygen delivery to COVID patients by nearly ten times, meaning that an oxygen tank that would typically last less than a day could last more than one week. If deployed, the technology could make an incredible difference in places like India, where access to oxygen is currently rationed on a triage basis.
“The support of the OBIO program has been invaluable in advancing this technology towards clinical use,” said Joel Ironstone, president of Ironstone Product Development. “The funding helped us conduct a trial to demonstrate the technology’s ability to dramatically reduce oxygen consumption while providing the same or potentially improved support to hypoxic patients, allowing us to positively contribute to the pandemic effort.”
OBIO undertook years of consultation with industry and the healthcare system to develop EAHN. Healthcare companies and healthcare organizations wishing to be part of EAHN should send proposals or requests for additional information to OBIO at [email protected]
OBIO®, founded in 2009, is a non-profit, member-based innovation organization engaged in strategy, programming, policy development and advocacy to promote the commercialization of technologies of the human health, positioning Canada as a leader in the international market. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the healthcare system and government.